MONTREAL, QUEBEC--(MARKET WIRE)--Jul 12, 2007 -- MethylGene Inc. (Toronto:MYG.TO - News), along with its partner Pharmion Corporation (NasdaqGM:PHRM - News), today announced the initiation of a single-agent Phase II clinical trial with its isotype-specific histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in patients with refractory chronic lymphocytic leukemia (CLL). Candidates for this study are adult patients who have refractory CLL or who are not candidates for current standard treatment options.